Completed PHASE2 INTERVENTIONAL 3-arm NCT04498650

A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD (VIVIAD)

A Phase 2b Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Dose Finding, Safety, Tolerability and Efficacy Study of PQ912 in Subjects With MCI and Mild Dementia Due to Alzheimer's Disease.

Sponsor: Amsterdam UMC, location VUmc

Conditions Early Alzheimers Disease Mild Cognitive Impairment Due to AD

Interventions PQ912 Placebo

Updated 16 times since 2020 Last updated: Mar 11, 2024 Started: Jul 6, 2020 Primary completion: Dec 18, 2023 Completion: Jan 12, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Early Alzheimers Disease and Mild Cognitive Impairment Due to AD and is currently completed. Amsterdam UMC, location VUmc leads this study, which shows 16 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

16 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2024 — Jul 2024 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Oct 2023 — Apr 2024 [monthly]

Active Not Recruiting PHASE2

▶ Show 11 earlier versions

Jan 2023 — Oct 2023 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Sep 2022 — Jan 2023 [monthly]

Recruiting PHASE2
May 2022 — Sep 2022 [monthly]

Recruiting PHASE2
Mar 2022 — May 2022 [monthly]

Recruiting PHASE2
Oct 2021 — Mar 2022 [monthly]

Recruiting PHASE2
Jun 2021 — Oct 2021 [monthly]

Recruiting PHASE2
May 2021 — Jun 2021 [monthly]

Recruiting PHASE2
Feb 2021 — May 2021 [monthly]

Recruiting PHASE2
Jan 2021 — Feb 2021 [monthly]

Recruiting PHASE2
Nov 2020 — Jan 2021 [monthly]

Recruiting PHASE2
Sep 2020 — Nov 2020 [monthly]

Recruiting PHASE2

First recorded

Jul 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amsterdam UMC, location VUmc
Nordic Bioscience A/S
Vivoryon Therapeutics N.V.

Data source: Vivoryon Therapeutics N.V.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

's-Hertogenbosch, Netherlands , Amsterdam, Netherlands , Barcelona, Spain , Berlin, Germany , Bialystok, Poland , Ganderup, Denmark , Getxo, Spain , Herlev, Denmark , Kiel, Germany , Lodz, Poland and 9 more locations